Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

BACKGROUND: Precision oncology medicines represent a paradigm shift compared to non-precision oncology medicines in cancer therapy, in some situations delivering more clinical benefit, and potentially lowering healthcare costs. We determined whether employing a companion diagnostic (CDx) approach du...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Raymond H., French, Declan, Stewart, Elaine, Smart, Dave, Idica, Adam, Redmond, Sandra, Eckstein, Markus, Clark, Jordan, Sullivan, Richard, Keeling, Peter, Lawler, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320864/
https://www.ncbi.nlm.nih.gov/pubmed/37408046
http://dx.doi.org/10.1186/s40545-023-00590-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320864/
https://www.ncbi.nlm.nih.gov/pubmed/37408046
http://dx.doi.org/10.1186/s40545-023-00590-9

Ejemplares similares